Karyopharm shares crater 65% after Xpovio fails Phase 3 endometrial cancer trial; company pivots to myelofibrosis label bid.
Karyopharm’s stock has plummeted after its second attempt to expand its blood cancer medicine Xpovio into endometrial cancer fell short.
Late Thursday, the company
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio…
Elicio's KRAS cancer vaccine failed to cut recurrence or death vs. observation in a 144-patient Phase 2 trial, plunging shares…
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company…
The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain,…
Back in March, Roche revealed that its breast cancer pill had failed in a pivotal Phase 3 trial. Data presented at ASCO reveal…
